Dizal Pharmaceutical(688192)2025-04-29 13:35Financial Performance - The company's operating revenue for Q1 2025 reached ¥159,641,464.34, representing a 96.32% increase compared to ¥81,318,560.00 in the same period last year[4] - The net loss attributable to shareholders was ¥192,513,348.95, an improvement from a loss of ¥224,234,890.87 year-over-year[4] - The total operating revenue for Q1 2025 was CNY 159,641,464.34, a significant increase from CNY 81,318,560.00 in Q1 2024, representing a growth of approximately 96%[19] - The net loss for Q1 2025 was CNY 193,740,729.91, an improvement from a net loss of CNY 224,234,890.87 in Q1 2024, reflecting a reduction in losses of approximately 14%[20] - The basic and diluted earnings per share for Q1 2025 were both CNY -0.46, compared to CNY -0.54 in Q1 2024, showing an improvement in earnings per share[21] Research and Development - Research and development expenses totaled ¥210,333,356.42, a slight increase of 2.72% from ¥204,770,425.91 in the previous year[5] - The ratio of R&D expenses to operating revenue decreased to 131.75%, down from 251.81% in the previous year, indicating a significant increase in revenue[5] - Research and development expenses for Q1 2025 were CNY 210,333,356.42, slightly up from CNY 204,770,425.91 in Q1 2024, showing a year-over-year increase of about 2%[20] - The new drug application for Shuwozhe® has been accepted by the FDA with priority review designation for specific lung cancer patients[12] - The company’s new molecule GW5282 has been approved to commence Phase I clinical trials in China[13] - DZD8586's latest clinical data has been selected for oral presentation at the 2025 ASCO conference, highlighting its significance in chronic lymphocytic leukemia treatment[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,804,839,457.76, reflecting a 5.01% increase from ¥1,718,737,884.05 at the end of the previous year[5] - Total current assets reached RMB 1.02 billion as of March 31, 2025, compared to RMB 998.97 million at the end of 2024[16] - The total non-current assets were CNY 784,132,605.39, up from CNY 719,765,080.27, reflecting an increase of approximately 9%[18] - Total liabilities increased to CNY 1,781,305,350.81 from CNY 1,518,680,986.42, representing a growth of about 17%[18] - The equity attributable to shareholders decreased by 90.47% to ¥18,460,390.68 from ¥193,755,800.40 at the end of the previous year[5] - The company's total equity decreased to CNY 23,534,106.95 from CNY 200,056,897.63, indicating a decline of about 88%[18] Cash Flow - The company reported a net cash flow from operating activities of -¥131,666,959.46, slightly worse than -¥126,071,888.78 in the previous year[4] - The company's cash flow from operating activities for Q1 2025 was CNY 164,190,860.93, compared to CNY 96,462,224.00 in Q1 2024, indicating a substantial increase in cash inflow[23] - Net cash flow from operating activities was -126.07 million in the previous period, indicating a slight increase in cash outflow[24] - Cash inflow from operating activities totaled 125.11 million, indicating a growth of about 51.5%[24] - Total cash inflow from investment activities was 1.03 billion in the previous period, reflecting a decrease of approximately 29%[24] - Cash outflow for investment activities totaled 1.09 billion previously, showing a reduction of about 21%[24] - Net cash flow from financing activities was 207.57 million in the prior period, representing a growth of approximately 26.5%[25] Government Support - The company received government subsidies amounting to ¥23,396,000.00, which are closely related to its normal business operations[6] Inventory and Assets - The company’s inventory decreased to RMB 37.54 million as of March 31, 2025, down from RMB 44.11 million at the end of 2024[16] - The company’s long-term assets include fixed assets valued at RMB 19.74 million and intangible assets valued at RMB 421.38 million as of March 31, 2025[16] - The company’s cash and cash equivalents amounted to RMB 252.51 million as of March 31, 2025, slightly up from RMB 250.16 million at the end of 2024[16]